Best Cardiac and Vascular Disorders Companies in Pennsylvania, United States
The 53 best Cardiac and Vascular Disorders companies in Pennsylvania, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Orchestra BioMed.
Ranked: Best Cardiac and Vascular Disorders companies in Pennsylvania
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Orchestra BioMed Developer of medical devices for hypertension and atherosclerosis treatment | $206M | 11 mo ago | 47 | Darren Sherman President | Public | Top 10M | — | 1 partnership |
| 2 | Mineralys Therapeutics Developer of therapy for the treatment of hypertension | $158M | 29 mo ago | 28 | — | Public | Top 5M | — | — |
| 3 | Nectero Medical Developer of a device for the treatment of abdominal aortic aneurysms | $116M | 27 mo ago | 6 | — | Series D | Top 50M | — | — |
| 4 | Cardiokine Therapeutics for cardiovascular diseases. | $87M | 242 mo ago | 15 | — | Acqui-Hired | — | — | — |
| 5 | Cagent Vascular Developer of a device for removal of vascular blockages 57Moat top 21%Funding top 24%Patents top 30%Innovation top 31% All 9 signals ▾Moattop 21% Fundingtop 24% Patentstop 30% Innovationtop 31% Techtop 34% Talentbottom 49% Globalbottom 45% Marketbottom 39% Newsbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 117 patents Funding: Raised $54.4M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 57/100 | $54M | 2 mo ago | 40 | Robert Giasolli Founder | Series D | Top 50M | 117 patents Drug‑coated, serrated‑balloon catheters for targeted vascular lesion therapy | 1 launch |
| 6 | Vesper Medical Provider of venous stent system | $52M | 85 mo ago | 22 | — | Acquired | — | — | — |
| 7 | XyloCor Therapeutics Developer of gene therapies for the treatment of coronary arterial disease | $43M | 18 mo ago | 18 | Ronald Crystal Co-Founder | Series B | Top 50M | — | — |
| 8 | TandemLife Advanced circulatory support systems and devices, educational resources, and customer support | $33M | 305 mo ago | 65 | George Magovern Co-Founder & Director | Acquired | — | — | — |
| 9 | Micro Interventional Transcatheter cardiac repair devices improving structural heart disease treatment | $25M | 43 mo ago | 7 | — | Series D | — | 59 patents Patents concentrated in health & consumer products | — |
| 10 | LifeLens Developer of wireless ECG monitor for personal health monitoring use 37Talent top 28%Funding top 32%Product top 35%Moat top 38% All 9 signals ▾Talenttop 28% Fundingtop 32% Producttop 35% Moattop 38% Techbottom 48% Innovationbottom 47% Marketbottom 34% Patentsbottom 32% Globalbottom 31% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $24.6M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $25M | 8 mo ago | 45 | David Robins Co-Founder | Series B | Top 50M | 5 patents Non‑invasive physiological monitoring and diabetes screening devices | — |
| 11 | Essential Medical Vascular closure devices | $23M | 95 mo ago | 20 | — | Acqui-Hired | — | — | — |
| 12 | Thrombolex Developer of endovascular catheters for acute venous thromboembolic conditions | $18M | 4 mo ago | 18 | — | Series A | Top 50M | 41 patents Thrombolex patents cover catheter-based thrombus removal baskets and infusion delivery systems. | 3 launchs |
| 13 | Excision Medical Developer of a medical device to treat valvular heart disease | $18M | 22 mo ago | 9 | David Wood Co-Founder | Series B | — | — | — |
| 14 | Bioconnect Systems Domain registration email verification service ensuring website availability | $18M | 153 mo ago | 3 | Adam Dakin Co-Founder & CEO | Deadpooled | — | — | — |
| 15 | Caliber Therapeutics Biomedical innovation company developing transformative therapeutic products for unmet medical needs | $13M | 105 mo ago | 12 | Darren Sherman CEO & Director | Series B | — | — | — |
| 16 | Intelomed Non-invasive sensor platform for cardiovascular monitoring | $13M | 114 mo ago | 5 | — | Series B | — | 64 patents Non‑invasive pulse‑volume waveform monitoring for respiratory and cardiovascular stress detection | — |
| 17 | Renovacor Developer of drugs for the treatment of cardiovascular and CNS disorders | $11M | 83 mo ago | 19 | Magdalene Cook CEO | Acquired | — | 10 patents Retrograde coronary venous/sinus drug delivery for cardiac therapeutics | — |
| 18 | Renovacor Develops gene-therapy based therapeutics solution for cardiac diseases | $11M | — | — | Magdalene Cook CEO & President | Early Stage | — | 10 patents Retrograde coronary venous/sinus delivery of therapeutic agents for cardiac treatment | — |
| 19 | Epitek Anchorage Closure Device | $9M | 205 mo ago | 37 | Steven Baronowitz CEO | Series A | — | 23 patents Patents concentrated in health & consumer products | — |
| 20 | Prolocor Developer of a diagnostic test for cardiovascular diseases | $6M | 28 mo ago | 5 | David Schneider Co-Founder | Seed | — | — | — |
| 21 | PECA Labs Developer of pediatric cardiac surgical devices | $6M | 8 mo ago | 11 | Arush Kalra Co-Founder/Chief Scientific Officer | Series B | Top 50M | 28 patents Expandable cardiovascular implants and polymer-based stent/valve devices for minimally invasive procedures. | — |
| 22 | Forest Devices Provider of a stroke screening device for medical personnel in outpatient clinics | $6M | 56 mo ago | 8 | Carmelo Montalvo Co-founder | Seed | — | 42 patents Integrated EEG headgear with built‑in electrode array and gel delivery for neurodiagnostics | — |
| 23 | Duska Therapeutics Developer of therapies for treating cardiovascular disease | $6M | 225 mo ago | — | Amir Pelleg Founder & President | Deadpooled | — | — | — |
| 24 | Thubrikar Aortic Valve Innovating durable transcatheter aortic valve technology for improved patient outcomes | $4M | 96 mo ago | 4 | — | Series A | — | 29 patents Transcatheter aortic valve prostheses and catheter-based delivery system technologies. | — |
| 25 | Pinmed Personalized intelligent medicine through hardware, software, and custom solutions | $2M | 144 mo ago | 2 | — | Funding Raised | — | — | — |
| 26 | Shifa Biomedical Developer of therapeutics for the treatment of cardiovascular disease | $2M | 22 mo ago | 6 | — | Seed | — | 53 patents Patents concentrated in chemistry & materials | — |
| 27 | WaveClear Vascular Developer of smart devices for treating peripheral vascular diseases | $1M | 9 mo ago | 3 | Jeffrey Vaitekunas Founder | Series A | — | — | — |
| 28 | NanoCell Therapeutics Developer of biological entity-based targeted gene therapy platform | $1M | 39 mo ago | — | Maurits Geerlings Co-Founder | Funding Raised | — | — | — |
| 29 | Vivasc Therapeutics Developer of drugs for cardiac treatments | $612K | 48 mo ago | 2 | Matthew Captline Co-Founder | Funding Raised | — | — | — |
| 30 | Neoolife Developer of a device for cardiovascular disease treatment | $554K | 38 mo ago | — | David Kokot Managing Director & Co-Founder | Funding Raised | — | — | — |
| 31 | Prolifagen Developer of cardiac treatment based on microRNA technology | $524K | 10 mo ago | 3 | — | Series A | — | — | — |
| 32 | Pression Provider of non-invasive cardiac-gated compression therapy device | $400K | 63 mo ago | 6 | Adam Salamon Founder & CEO | Seed | — | 6 patents Medical limb compression devices for enhanced circulation and surgical applications. | — |
| 33 | NeuRx Medical Developer of medical devices for image-guided thrombectomy procedures | $256K | 52 mo ago | 1 | — | Funding Raised | — | — | — |
| 34 | QLIDA Diagnostics Portable, Handheld Biomarker detection platform | $250K | 155 mo ago | — | Michael Neidrauer CSO & Founder | Deadpooled | — | — | — |
| 35 | Forge Medical Hemostasis device company providing solutions for vascular access site management | $180K | 176 mo ago | 7 | Timothy Clark CEO and Chairman | Seed | — | — | — |
| 36 | RTM Vital Signs Real-time implantable blood pressure sensor and vital sign monitoring system | $175K | 16 mo ago | 2 | Jeff Joseph Co-Founder | Seed | — | 47 patents Acoustic respiratory monitoring sensors and implantable cardiovascular monitoring devices | — |
| 37 | GrantAdler Vascular access products | $100K | 200 mo ago | — | Mike Loiterman Co-Founder | Deadpooled | — | 6 patents Subcutaneous port needles and elastic tubing interconnect medical device components | — |
Top 12 Cardiac and Vascular Disorders companies in Pennsylvania
#1
Series D · Wayne, Pennsylvania · founded 2014 · 40 employees$54.4Mraised▾
Developer of a device for removal of vascular blockages. The company is developing a Lesion Preparation balloon designed to enable more effective removal of blockages in blood vessels and to increase drug uptake when used along with a Drug-Coated Balloon. Their technology has applications in the treatment of Peripheral arterial disease.
- May 2026Series D$41M
- Feb 2025Series C$15M
- Jan 2024Series C$30M
- Jun 2021Series B$9.5M
#2
Public · New Hope, Pennsylvania · founded 2017 · 47 employees$205.9Mraised▾
Developer of medical devices for hypertension and atherosclerosis treatment. The companies product portfolio includes Virtue Sirolimus-Eluting Balloon and BackBeat Cardiac Neuromodulation Therapy. Virtue Sirolimus-Eluting Balloon delivers delayed-release bioabsorbable particle encapsulated Sirolimus. This can be used for the prevention of restenosis of treated arteries.
- Jul 2025Post IPO$35M
- Jul 2022Series D$110M
- Dec 2019Venture Debt$20M
- Jul 2019Series B$34M
#3
Series A · Doylestown, Pennsylvania · founded 2016 · 18 employees$17.8Mraised▾
Developer of endovascular catheters for acute venous thromboembolic conditions. It has developed a proprietary endovascular catheter device called BASHIR which is used for the localized infusion of biological fluids. Its BASHI N-X is also intended for the localized infusion of biological fluids into the peripheral vasculature and pulmonary arteries.
- Feb 2026Series A$50M
- Jun 2024Series A$1.2M
- Jun 2023Series A$4.8M
- Aug 2022Series A$2M
#4
Series B · Warminster, Pennsylvania · founded 2014 · 45 employees$24.6Mraised▾
Developer of wireless ECG monitor for personal health monitoring use. The monitor is indicated for use on patients who may be asymptomatic. It can also be used for patients who may suffer from transient symptoms. These symptoms include palpitations, shortness of breath, dizziness, and fatigue. The monitor is intended for use by patients eighteen years or older. The system is not yet cleared for other indications.
- Nov 2025Series B$15.1M
- Jun 2024Series B$18.4M
- Sep 2021Series A$78.2K
- Jul 2020Series A$3.2M
#5
Series B · Pittsburgh, Pennsylvania · founded 2011 · 11 employees$6Mraised▾
Developer of pediatric cardiac surgical devices. PECA Labs has developed the MASA valve, a synthetic valved conduit for pediatric right ventricular outflow tract reconstruction. Uses ePTFE material and RVOT-specific design to differentiate from existing alternatives. PECA is developing a valved RV-PA shunt for the treatment of hypoplastic left heart syndrome (HLHS). This device is expected to decrease the high mortality and morbidity rates associated with the Norwood Procedure.
- Nov 2025Series B$2.7M
- Dec 2024Series B$13.9M
- Nov 2022Conventional Debt$618.2K
- Jun 2021Series A$99.2K
#6
Series B · Newtown Square, Pennsylvania · founded 2013 · 18 employees$43.4Mraised▾
XyloCor Therapeutics is developing gene therapies for coronary arterial disease. Its lead candidate, XC001, is for patients with refractory angina with no treatment options, and its secondary product for patients with cardiac tissue damage from heart attacks. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. The second candidate, XC002 is in the discovery stage and involves the regeneration of cardiac tissue for cases with past heart attacks.
- Jan 2025Series B$67.5M
- Mar 2021Series A$22.6M
- Jan 2021Series A$4M
- Oct 2018Series A$16.8M
#7
Series B · Malvern, Pennsylvania · founded 2020 · 9 employees$17.6Mraised▾
Developer of a medical device to treat valvular heart disease. The company has developed a "Leaflet Excision System" to target and excise one or more aortic valve leaflets and integrate them into the workflow of transcatheter aortic valve replacement procedures.
- Sep 2024Series B$10.3M
- Dec 2023Series A$2M
- Mar 2023Series A$3M
- Dec 2022Seed$1.9M
#8
Public · Radnor, Pennsylvania · founded 2020 · 28 employees$158Mraised▾
Developer of therapy for the treatment of hypertension. The company's product MLS-101 is a selective aldosterone synthase inhibitor for elevated aldosterone that is the cause of hypertension. It reduces aldosterone without affecting other hormones like cortisol and treats the blood pressure in hypertension patients.
- Feb 2024Post IPO—
- Jun 2022Series B$118M
- Apr 2021Series A$40M
#9
Series D · Bethlehem, Pennsylvania · founded 2019 · 6 employees$115.5Mraised▾
Developer of a device for the treatment of abdominal aortic aneurysms. The company has an endovascular aneurysm stabilization treatment system that delivers a stabilizer agent to the site of the aneurysm. It stabilizes the aneurysm by reducing the growth rate and strengthening the aortic tissue.
- Apr 2024Series D$96M
- Sep 2021Series C$19.5M
- Apr 2020Series B—
#10
Series A · Erie, Pennsylvania · founded 2020 · 3 employees$1.3Mraised▾
Developer of smart devices for treating peripheral vascular diseases. The company has developed a smart device that utilizes the piezoelectric effect to generate ultrasonic energy in wires. It contains the wire tapers at key locations so that it manages the longitudinal waves and helps to increase in amplitude near the end of the wire. The device converts the longitudinal waves into transverse waves.
- Oct 2025Series A$3.5M
- Feb 2022Series A$150K
- Oct 2020Series A$1.1M
#11
Series A · Villanova, Pennsylvania · founded 2016 · 3 employees$524.4Kraised▾
Developer of cardiac treatment based on microRNA technology. The Mir302 is a microRNA that activates the cardiomyocyte proliferation and regeneration of cardiac function that helps in the prevention of heart failure.
- Sep 2025Series A$302.7K
- May 2019Grant (prize money)$221.7K
#12
Seed · Malvern, Pennsylvania · founded 2006 · 6 employees$1.8Mraised▾
Developer of therapeutics for the treatment of cardiovascular disease. It works on the development of drugs for the treatment of cancer and cardiovascular diseases and the development of vaccine technology. The company develops drugs to lower bad cholesterol by targeting PCSK9 which eventually controls LDLR levels. The lead compound is P-21, an oral therapeutic that interferes with the function of PCSK9.
- Sep 2024Grant (prize money)$1.3M
- May 2021Seed$1.8M
- May 2020Grant (prize money)$1.9M
- Aug 2019Grant (prize money)$286.9K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.